Sciclone Pharmaceuticals Inc
SCLN
SCLN was delisted on the 13th of October, 2017.
102 hedge funds and large institutions have $148M invested in Sciclone Pharmaceuticals Inc in 2013 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 41 increasing their positions, 34 reducing their positions, and 16 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 34
1% more capital invested
Capital invested by funds: $147M → $148M (+$983K)
2% less funds holding
Funds holding: 104 → 102 (-2)
13% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$4.2M |
| 2 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
+$3.55M |
| 3 |
Renaissance Technologies
New York
|
+$2.06M |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$2.02M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Schroder Investment Management Group
London,
United Kingdom
|
-$11.4M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
-$2.29M |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$1.81M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$1.58M |
| 5 |
Morgan Stanley
New York
|
-$1M |
SCLN Hedge Fund Activity: Q3 2013 in Review
102 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals Inc (SCLN) for Q3 2013, worth a combined $148M — up 0.67% from $147M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of SCLN and 14 opened new positions — a net loss of 2 holders — while 34 trimmed existing stakes and 41 added.
The largest buyer was Acadian Asset Management, adding an estimated $4.2M. The largest seller was Schroder Investment Management Group, cutting an estimated $11.4M.
- 102 institutional investors held Sciclone Pharmaceuticals Inc (SCLN) as of Q3 2013, down from 104 in Q2 2013.
- Funds reported $148M of Sciclone Pharmaceuticals Inc stock for Q3 2013, up 0.67% quarter-over-quarter.
- 14 funds opened new Sciclone Pharmaceuticals Inc positions in Q3 2013 and 16 closed out, a net change of -2 holders.
- The largest Sciclone Pharmaceuticals Inc buyer in Q3 2013 was Acadian Asset Management, an estimated $4.2M added.
- The largest Sciclone Pharmaceuticals Inc seller in Q3 2013 was Schroder Investment Management Group, an estimated $11.4M sold.
Based on aggregated 13F filings for Q3 2013.